Showing 4271-4280 of 4924 results for "".
- New Survey: AD Is More Than Skin Deephttps://practicaldermatology.com/news/new-survey-ad-is-more-than-skin-deep/2458417/American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as New York dermatologist Doris Day, MD, who notes that some of the results of the large suvey w
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Ac
- Game Change: The New Global Psoriasis Atlas to Accrue Worldwide PsO Datahttps://practicaldermatology.com/news/game-change-the-new-global-psoriasis-atlas-to-accrue-worldwide-pso-data/2458419/Three global health organizations are joining forces to launch the Global Psoriasis Atlas (GPA), the first-ever worldwide database on psoriasis. The GPA project comes in response to the 2016 World Health Organization (WHO) Global Report on
- Research Elucidates Skin Phenotype of Pediatric Eczemahttps://practicaldermatology.com/news/research-elucidates-skin-phenotype-of-pediatric-eczema/2458426/Pediatric atopic dermatitis (AD) in infants looks a lot different than adult AD, suggesting the need for alternative, and possibly more aggressive, treatment strategies in children. The study, led by researchers at the Icahn School of Medicine at Mount Sina
- National Rosacea Society Awards Three New Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-three-new-grants/2458430/The National Rosacea Society (NRS) is funding three new studies in addition to continuing support for two ongoing studies as part of its research grants program. In this round, Luis Garza, MD, an associate professor of dermatology at Johns Hopk
- Ditch the Itch: EpiCeram Helps Relieve Eczema Symptomshttps://practicaldermatology.com/news/ditch-the-itch-epiceram-helps-relieve-eczema-symptoms/2458431/A new survey from PuraCap Pharmaceutical sheds light on the emotional and physical effects of eczema, a pervasive condition that affects 31.6 million people in the US. According to the survey, a large number of people are not getting the relief they need
- Venus Concept Unveils Venus Freeze Plus for Non-Invasive Anti-Aging Treatmentshttps://practicaldermatology.com/news/venus-concept-unveils-venus-freeze-plus-for-non-invasive-anti-aging-treatments/2458432/Venus Concept's non-invasive anti-aging device, Venus Freeze Plus, is now available in the US. It is indicated for the treatment of moderate-to-severe facial wrinkles and rhytides, leading to the tightening of the skin, with no pain or downtime. Venus Freeze Plus works by using Venus
- Save the Date: Sept 28th Marks First Ever PsA Awareness Dayhttps://practicaldermatology.com/news/save-the-date-sept-28-is-first-psa-awareness-day/2458433/September 28th marks the first-ever Psoriatic Arthritis (PsA) Awareness Day. Launched by Celgene Corporation and the National Psoriasis Foundation (NPF), PsA Awareness Day is dedicated to education, empowerment, and action for the PsA community. PsA patients can
- Skin Cancer Prevention Barriers Cited in Uninsured, Minority, Immigrant Populationshttps://practicaldermatology.com/news/skin-cancer-prevention-barriers-cited-in-uninsured-minority-immigrant-populations/2458434/Lack of knowledge, the belief that dark skin is protective, and the dislike of sun protection are barriers to skin cancer prevention in minority and immigrant populations, according to a new study in JAMA Dermatology.
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).